Leukemia-cell parameters associated with aggressive disease independent of the disease stage
Parameter . | Reference . |
|---|---|
| Aberrations in chromosomes 11 (11q-) or 17 (17p-) | Döhner et al5 |
| Lack of somatic mutations in the expressed immunoglobulin VH-genes | Hamblin et al6 ; Damle et al7 |
| Expression of cytoplasmic ZAP-70 | Rassenti et al8 ; Crespo et al9 ; Orchard et al10 |
| Short lymphocyte doubling time (less than 12 months) | Montserrat et al11 |
| Elevated serum levels of β2-microglobulin | Keating et al12 ; Hallek et al13 |
| Elevated serum levels of soluble CD23 | Reinisch et al14 ; Sarfati et al15 |
| Elevated serum thymidine kinase activity | Hallek et al16 |
| Leukemia cell-surface expression of CD38 | Damle et al7 ; Ibrahim et al17 |
Parameter . | Reference . |
|---|---|
| Aberrations in chromosomes 11 (11q-) or 17 (17p-) | Döhner et al5 |
| Lack of somatic mutations in the expressed immunoglobulin VH-genes | Hamblin et al6 ; Damle et al7 |
| Expression of cytoplasmic ZAP-70 | Rassenti et al8 ; Crespo et al9 ; Orchard et al10 |
| Short lymphocyte doubling time (less than 12 months) | Montserrat et al11 |
| Elevated serum levels of β2-microglobulin | Keating et al12 ; Hallek et al13 |
| Elevated serum levels of soluble CD23 | Reinisch et al14 ; Sarfati et al15 |
| Elevated serum thymidine kinase activity | Hallek et al16 |
| Leukemia cell-surface expression of CD38 | Damle et al7 ; Ibrahim et al17 |